Genzyme Targets InvaGen Over Kidney Treatment Generics
Genzyme brought the complaint to defend its $700 million share of the kidney disease treatment market from enroaching generics. It claims that InvaGen's treatment would violate its patented drug composition and deflate the demand for its own products.
Genzyme says it received a letter from InvaGen in January notifying the company of a...
Already a subscriber? Click here to login